To include your compound in the COVID-19 Resource Center, submit it here.

ArunA’s exosome entrance

Why ArunA decided to develop exosome therapeutics for stroke

Stem cell manufacturer ArunA Biomedical Inc. has announced a pivot into the exosome therapeutic space, as well as publication of the first data showing its neural stem cell-derived exosomes and other extracellular vesicles are effective in mouse models of stroke.

ArunA launched in 2003 to provide stem cells to the research community.

According to co-founder, CEO and CSO Steven Stice, the company’s move into therapeutics development was driven by opportunities it saw arising in

Read the full 729 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers